Crescent Biopharma
CBIO
47 hedge funds and large institutions have $42.7M invested in Crescent Biopharma in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
0% more funds holding
Funds holding: 47 → 47 (0)
0% less ownership
Funds ownership: 0.58% → 0.57% (-0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
21% less call options, than puts
Call options by funds: $450K | Put options by funds: $568K
34% less capital invested
Capital invested by funds: $64.9M → $42.7M (-$22.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$442K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$335K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$265K |
| 4 |
Two Sigma Investments
New York
|
+$203K |
| 5 |
EP
Eversept Partners
New York
|
+$181K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$799K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$617K |
| 3 |
VF
Virtu Financial
New York
|
-$119K |
| 4 |
HF
HRT Financial
New York
|
-$112K |
| 5 |
D.E. Shaw & Co
New York
|
-$88.7K |
CBIO Hedge Fund Activity: Q4 2021 in Review
47 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2021, worth a combined $42.7M — down 34% from $64.9M a quarter earlier.
Fund positioning in CBIO was balanced in Q4 2021: 6 funds opened new positions, 6 closed out, 15 added to existing stakes and 13 trimmed.
The largest buyer was Millennium Management, adding an estimated $442K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $799K sold.
- 47 institutional investors held Crescent Biopharma (CBIO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $42.7M of Crescent Biopharma stock for Q4 2021, down 34% quarter-over-quarter.
- 6 funds opened new Crescent Biopharma positions in Q4 2021 and 6 closed out, a net change of 0 holders.
- The largest Crescent Biopharma buyer in Q4 2021 was Millennium Management, an estimated $442K added.
- The largest Crescent Biopharma seller in Q4 2021 was Jacobs Levy Equity Management, an estimated $799K sold.
Based on aggregated 13F filings for Q4 2021.